This Site uses technical and third party cookies, to ensure its technical functioning and analyse visitor information in aggregate form. By closing this banner, selecting any link or continuing to browse by accessing any other section of this Site, you consent to the use of cookies. For more information on cookies, set your preferences or deny your consent, please click on the following link “Cookie Policy” available at the bottom of any www.diasorin.com website page under section “Privacy Policy”. I agree GROUP WEBSITES MENU CORPORATE DOCUMENTS (ETHIC CODE, PRIVACY POLICY AND LEGAL NOTE) AVAILABLE ON DIASORIN CORPORATE LIAISON® MeMed BV® The innovative new solution for accurate and rapid differentiation between bacterial and viral infections READ MORE SCOPRI DI PIÙ DIASORIN, THE DIAGNOSTIC SPECIALIST We are global leader in the laboratory diagnostics market, specializing in the immunodiagnostics and molecular diagnostics segments. For over 50 years our Group has been developing, producing and commercializing diagnostic tests: we support clinical laboratory needs and activities, providing solutions that are reliable, innovative, fully automated and standardized. We continually invest in Research & Development, using our own distinctive expertise in the field to deliver a high level of innovation. OUR COMPANY CLINICAL AREAS We offer the broadest range of specialty tests available in the immunodiagnostics market. DISCOVER ALL AREAS DISCOVER OUR MENU LIAISON® XS All our technology in a new dimension. LIAISON® XS delivers a high technology solution for immunochemistry tests that allows laboratories to improve efficiency and clinical effectiveness for routine and specialty testing. DISCOVER ALL SYSTEMS WORLDWIDE PRESENCE Our Group consists of 22 branches with offices across 5 continents and manufacturing premises producing its tests in 5 sites around the world. WHERE WE ARE NEWS 14/07/2021 The acquisition of Luminex Corporation represents an important step in the expansion strategy of DiaSorin… Read the press release 12/07/2021 ECCMID ‘21: Integrated Symposium Diagnosis and immune response of SARS-CoV-2 infection, Flash session TrimericS IgG serology assay in heterologous vaccination. Register to access 08/02/2021 DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 TrimericS IgG assay, a new quantitative serology test for determination of IgG antibodies against SARS-CoV-2. Read the press release 26/10/2020 DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 Ag, a new high-throughput antigen test for COVID-19 detection in symptomatic patients. Read the press release ALL NEWS Discover DIASORIN APP FOR LABORATORIES NEW LABELING & PACKAGING Contacts HEADQUARTER Via Crescentino Snc 13040 Saluggia (VC) Centralino Tel. +39 0161 487.1 MARKETING Tel. +39 0161 487.1 marketing@diasorin.it Diasorin Group Diasorin Molecular Luminex Corporation Privacy Policy Legal Notices Modern Slavery Act Statement DiaSorin S.p.A. - Capitale Sociale €55.948.257 R.E.A. 180729 Fiscal Code and Subscription to Vercelli Companies Register no 13144290155